Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BGT226 |
Synonyms | |
Therapy Description |
BGT226 is a dual inhibitor of class I PI3K kinases and mTOR, which may inhibit tumor celll proliferation and tumor growth (PMID: 21976531, PMID: 31190275). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BGT226 | NVP-BGT226 | mTOR Inhibitor 51 PI3K Inhibitor (Pan) 42 | BGT226 is a dual inhibitor of class I PI3K kinases and mTOR, which may inhibit tumor celll proliferation and tumor growth (PMID: 21976531, PMID: 31190275). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | acute lymphoblastic leukemia | sensitive | BGT226 | Preclinical - Cell culture | Actionable | In a preclinical study, BGT226 treatment in PTEN-deficient acute lymphoblastic leukemia cells resulted in inhibition of PI3K/Akt signaling and apoptotic activity in culture (PMID: 23705826). | 23705826 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|